Table 2 Current clinical trail data of Checkpoint targets and agents

CTLA-4

Tremelimumab

Human

NCT02716805

Phase 1 trail in MM

In combination of Durvalumab, High-dose Chemotherapy after ASCT

Terminated

PD-1

Pembrolizumab

Humanized

NCT03848845

Phase 1 trail in RRMM

In Combination With GSK2857916

Active, not recruiting

NCT02576977

Phase 3 trail in RRMM

Pomalidomide and Low Dose Dexamethasone with or without Pembrolizumab

Terminated

NCT02906332

Phase 3 trail in High-risk MM

In combination of lenalidomide post ASCT

Active, not recruiting

NCT03221634

Phase 2 trail in RRMM

In Combination With Daratumumab

Withdrawn

NCT05493618

Phase 1/2 trail in Refractory MM

In Combination With Belantamab and Dexamethasone

Not yet recruiting

NCT02579863

Phase 3 trail in NDMM

Lenalidomide and Dexamethasone with or without Pembrolizumab

Terminated

NCT03191981

Phase 1/2 trail in Refractory MM

In combination with Cyclophosphamide and Lenalidomide

Withdrawn

NCT02289222

Phase 1/2 trail in RRMM

In combination with IMiD (Pomalidomide)

Terminated

NCT05191472

Phase 2 trail in RRMM

In combination with Anti-BCMA CAR-T Therapies

Recruiting

Nivolumab

Human

NCT03227432

Phase 2 trail in RRMM

In Combination of Elotuzumab and Nivolumab with and without Pomalidomide

Withdrawn

NCT04119336

Phase 2 trail in RRMM

In Combination of Ixazomib, Cyclophosphamide, and Dexamethasone

Active, not recruiting

NCT02903381

A Phase 2 Trial in High Risk Smoldering MM

In combination with Lenalidomide and Dexamethasone

Suspended

NCT02612779

Phase 2 trail in RRMM

In combination with Elotuzumab

Completed

NCT02726581

Phase 2 trail in MM

In combination with Pomalidomide and Dexamethasone

Completed

cemiplimab

Human

NCT03194867

Phase 1/2 trail in RRMM

in combination with Isatuximab

Active, not recruiting

PD-L1

atezolizumab

Humanized

NCT03312530

Phase 1/2 trail in RRMM

In combination with Venetoclax, With or Without Atezolizumab

Completed

NCT02431208

Phase 1 trail in MM

Alone or in combination with IMiDs and/or Daratumumab

Completed

durvalumab

Human

NCT03000452

NCT02807454

Phase 2 trail in RRMM

In combination with Daratumumab

Completed

NCT02685826

Phase 1/2 trail in NDMM

In combination with Lenalidomide with and without Dexamethasone

Completed

CD47

TTI-622

Human

NCT05139225

Phase 1 trail in MM

In combination with Daratumumab Hyaluronidase-fihj

Recruiting

LAG-3

BMS-986016

Human

NCT04150965

Phase 1/2 trial in RRMM.Alone and in combination with Pomalidimide and Dexamethasone

Recruiting

TIGIT

BMS-986207

Human

NCT04150965

Phase 1/2 trial in RRMM.Alone and in combination with Pomalidimide and Dexamethasone

Recruiting

KIRs

IPH2101

Human

NCT00999830

Phase 2 trail in MM of two dose regimens (0.2 and 2 mg/kg)

Completed

NCT01222286

Phase 2 trail in smoldering MM of two dose regimens (0.2 and 2 mg/kg,every 4 weeks by intravenous route over 1 h, for 6 or up to 12 cycles)

Completed

NCT01217203

Phase 1 trail in MM

In combination of lenalidomide

Completed

NCT00552396

Phase 1 trail in RRMM

Completed

NCT01248455

Phase 2 trail in smoldering MM

(1 mg/kg) every other month for 6 cycles

Terminated

lirilumab

Human

NCT02252263

Phase 1 trial in MM.In combination with Elotuzumab